Home News Covid-19

Small is better for vaccine shares

Bloomberg11/25/2020 03:39 PM GMT+08  • 3 min read
Small is better for vaccine shares
Big vaccine news makes little difference to pharma giant shares.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Investors who bet on success in the race to develop coronavirus vaccines are finding that smaller is better.

Shares of BioNTech SE, the German startup that’s working with U.S. drug giant Pfizer Inc. to develop an innoculation, have almost tripled this year while its partner has slipped about 1%. And Moderna Inc., which went public less than two years ago, is up fivefold. AstraZeneca Plc, meanwhile, has gained 5.2%.

While all of those companies reported success this month in developing shots against the coronavirus, headline-grabbing news on a highly anticipated product just isn’t enough to boost shares of businesses as large as Pfizer and AstraZeneca -- even when they’re working on one of the most important vaccines ever.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now